Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06739122 · ClinicalTrials.gov registry record · Phase 3
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
A Phase 3 study of Type 2 Diabetes, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 55
- Enrollment target
- 20
- Study locations
NCT06739122 is a Phase 3 study of Type 2 Diabetes that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 55 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06739122, a Phase 3 study of Type 2 Diabetes, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 55 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Conditions Studied
Interventions
- DRUG Dulaglutide
Study Locations (20)
Florida
- Nemours Children's Health - Jacksonville
- D&H National Research Centers, Inc - Miami
- AdventHealth Orlando - Orlando
- D&H Tamarac Research Center, LLC - Tamarac
- University of South Florida - Tampa
California
- Division of Endocrinology, Diabetes, and Metabolism - Los Angeles
- UCLA Mattel Children's Hospital - Los Angeles
- University of California, San Francisco - San Francisco
District of Columbia
- Emerson Clinical Research Institute - Washington D.C.
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Center for Advanced Pediatrics - Atlanta
- Centricity Research Columbus Endocrinology - Columbus
Arizona
- University of Arizona - Tucson
Arkansas
- Arkansas Childrens Hospital - Little Rock
Colorado
- Children's Hospital of Colorado - Denver
Connecticut
- Yale Diabetes Research - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2025-01-10 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06739122
The ClinicalTrials.gov registry entry for NCT06739122 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (95% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Dulaglutide is the first listed.
NCT06739122 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06739122 about?
NCT06739122 is a clinical study titled "A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)". The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
What is the current status of trial NCT06739122?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 55 participants. The study started on 2025-01-10. Estimated completion is 2027-12.
What conditions does trial NCT06739122 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT06739122?
The interventions under investigation include: Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT06739122?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06739122 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.